196 related articles for article (PubMed ID: 15829410)
1. Immunomodulatory activity of analog of muramyl dipeptide and their use as adjunct to chemotherapy of Leishmania donovani in hamster.
Puri A; Sahai R; Haq W; Zaidi A; Guru PY; Tripathi LM; Srivastava VM
Int Immunopharmacol; 2005 Jun; 5(6):937-46. PubMed ID: 15829410
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
Sarkar K; Das PK
J Immunol; 1997 Jun; 158(11):5357-65. PubMed ID: 9164956
[TBL] [Abstract][Full Text] [Related]
3. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
4. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of immunomodulatory properties of muramyl peptides on immune system cells of young and old mice.
Dozmorov IM; Kuzin II; Lutsan NI; Lutsenko GV; Prokhorova AL; Sapozhnikov AM; Andronova TM; Ivanov VT
Immunopharmacol Immunotoxicol; 1994 May; 16(2):149-63. PubMed ID: 8077604
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
7. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
8. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulant activity of Picroliv, the iridoid glycoside fraction of Picrorhiza kurroa, and its protective action against Leishmania donovani infection in hamsters.
Puri A; Saxena RP; Sumati ; Guru PY; Kulshreshtha DK; Saxena KC; Dhawan BN
Planta Med; 1992 Dec; 58(6):528-32. PubMed ID: 1484891
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of human beta-casein fragment (54-59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters.
Sharma P; Singh N; Garg R; Haq W; Dube A
Peptides; 2004 Nov; 25(11):1873-81. PubMed ID: 15501518
[TBL] [Abstract][Full Text] [Related]
12. Glycyrrhizic acid suppresses Cox-2-mediated anti-inflammatory responses during Leishmania donovani infection.
Bhattacharjee S; Bhattacharjee A; Majumder S; Majumdar SB; Majumdar S
J Antimicrob Chemother; 2012 Aug; 67(8):1905-14. PubMed ID: 22589456
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulant activity of a novel lipopeptide and its protective action against Leishmania donovani.
Puri A; Rizvi SY; Haq W; Guru PY; Kundu B; Saxena RP; Shukla R; Mathur KB; Saxena KC
Immunopharmacol Immunotoxicol; 1993 Nov; 15(5):539-56. PubMed ID: 8301018
[TBL] [Abstract][Full Text] [Related]
14. [Muramyl dipeptide and its synthetic analog as possible inducers of interleukin-2 production].
Malaĭtsev VV; Bogdanov IM; Sukhikh GT; Andronova TM
Biull Eksp Biol Med; 1985 Aug; 100(8):221-3. PubMed ID: 3875372
[TBL] [Abstract][Full Text] [Related]
15. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
[TBL] [Abstract][Full Text] [Related]
16. [Changes in purine metabolism in the macrophages of mice exposed to a new synthetic analog of muramyl dipeptide].
Umanskiĭ VIu; Tarakhovskiĭ AM; Andronova TM
Biull Eksp Biol Med; 1985 Jun; 99(6):685-7. PubMed ID: 2990603
[TBL] [Abstract][Full Text] [Related]
17. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
18. Adjunct effect of immunostimulating hexapeptide analogous to human beta-casein fragment (54-59) to sodium stibogluconate against experimental visceral leishmaniasis.
Gupta S; Srivastava VM; Puri A; Pandey D; Haq W
Immunopharmacol Immunotoxicol; 2004 Aug; 26(3):425-34. PubMed ID: 15518175
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory activity of biopolymeric fraction RLJ-NE-205 from Picrorhiza kurroa.
Gupta A; Khajuria A; Singh J; Bedi KL; Satti NK; Dutt P; Suri KA; Suri OP; Qazi GN
Int Immunopharmacol; 2006 Oct; 6(10):1543-9. PubMed ID: 16919826
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
Bhardwaj S; Vasishta RK; Arora SK
Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
